The specific site of PD-L1 assessment was not clearly reported in these trials but a post hoc analysis of IMPassion130 revealed a difference in PD-L1 expression between primary tumor and metastatic sites (44% vs 36%, p=0.014) of mTNBC patients with no apparent influence on the predictive value of PD-L1 expression (59). The gene discussed is CD274; the disease is neoplasm.